John M. Burke MDRocky Mountain Cancer Center
*Describe treatment considerations for patients with chronic lymphocytic leukemia (CLL), including patient, disease, and treatment-related factors.
*Review clinical trial data regarding the role of Bruton tyrosine kinase (BTK) inhibitors in managing CLL.
*Design individualized treatment plans for patients with CLL, optimized in accordance with the latest expert recommendations and clinical trial data.
The goal of this learning module is to educate hematologists/oncologists and other members of the care team for patients with CLL on how to apply clinical data and expert recommendations to the application of novel and emerging therapies to treatment planning, including the use of BTK inhibitors. A leading expert presenter will guide learners through 1-2 patient cases, followed by a short discussion in Q & A format.
The content for this program has been independently developed by Clinical Care Solutions.